Safety of SGLT-2 inhibitors in the management of heart failure in the adult congenital heart disease patient population.

Journal: International journal of cardiology. Congenital heart disease
Published Date: Feb 17, 2024

Abstract

BACKGROUND: Sodium glucose transporter 2 inhibitors (SGLT-2i) have shown safety and efficacy in patients with heart failure (HF). However, evidence for the use of SGLT-2i in adult congenital heart disease (ACHD) patients with HF is limited.

Authors

  • Ahmed Kheiwa
    Division of Cardiology, Adult Congenital Heart Disease Program, Loma Linda University, Loma Linda, CA, USA.
  • Brian Ssembajjwe
    Division of Internal Medicine, Department of Medicine, Loma Linda University, Loma Linda, CA, USA.
  • Payush Chatta
    Division of Cardiology, Department of Medicine, Loma Linda University, Loma Linda, CA, USA.
  • Stephen Nageotte
    Division of Pediatric Cardiology, Loma Linda University Children's Hospital, Loma Linda, CA, USA.
  • Dmitry Abramov
    Division of Cardiology, Department of Medicine, Loma Linda University, Loma Linda, CA, USA.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals